In CRC anti-EGFR treatment, PCR-based assays with high sensitivity and specificity enable effective exclusion of patients with mutant KRAS, as well as reduce drug side effects and increase PFS and mOS in the wild-type KRAS patients. Here, KRAS is linked to colorectal carcinoma.